CN103270419B - 用于通过宫颈细胞的悬液样本预测受试者是否具有宫颈上皮内瘤样(cin)病变的方法和系统 - Google Patents
用于通过宫颈细胞的悬液样本预测受试者是否具有宫颈上皮内瘤样(cin)病变的方法和系统 Download PDFInfo
- Publication number
- CN103270419B CN103270419B CN201180061996.1A CN201180061996A CN103270419B CN 103270419 B CN103270419 B CN 103270419B CN 201180061996 A CN201180061996 A CN 201180061996A CN 103270419 B CN103270419 B CN 103270419B
- Authority
- CN
- China
- Prior art keywords
- cell
- sample
- data
- cervical
- cin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 98
- 206010008263 Cervical dysplasia Diseases 0.000 title claims abstract description 19
- 208000007951 cervical intraepithelial neoplasia Diseases 0.000 title claims abstract description 11
- 239000000725 suspension Substances 0.000 title claims description 10
- 230000003902 lesion Effects 0.000 title abstract description 44
- 239000000090 biomarker Substances 0.000 claims abstract description 100
- 239000007788 liquid Substances 0.000 claims abstract description 42
- 238000013425 morphometry Methods 0.000 claims abstract description 40
- 230000003562 morphometric effect Effects 0.000 claims abstract description 26
- 208000019065 cervical carcinoma Diseases 0.000 claims abstract description 23
- 239000000523 sample Substances 0.000 claims description 190
- 238000004458 analytical method Methods 0.000 claims description 24
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 238000001215 fluorescent labelling Methods 0.000 claims description 19
- 230000007774 longterm Effects 0.000 claims description 17
- 238000005259 measurement Methods 0.000 claims description 16
- 239000007850 fluorescent dye Substances 0.000 claims description 15
- 230000008823 permeabilization Effects 0.000 claims description 13
- 101150005988 cin2 gene Proteins 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 12
- 230000035945 sensitivity Effects 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 238000000684 flow cytometry Methods 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 7
- 238000001574 biopsy Methods 0.000 claims description 6
- 210000003679 cervix uteri Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 225
- 108020004414 DNA Proteins 0.000 description 41
- 230000002159 abnormal effect Effects 0.000 description 22
- 238000000149 argon plasma sintering Methods 0.000 description 19
- 239000003086 colorant Substances 0.000 description 17
- 238000001514 detection method Methods 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- KBTLDMSFADPKFJ-UHFFFAOYSA-N 2-phenyl-1H-indole-3,4-dicarboximidamide Chemical compound N1C2=CC=CC(C(N)=N)=C2C(C(=N)N)=C1C1=CC=CC=C1 KBTLDMSFADPKFJ-UHFFFAOYSA-N 0.000 description 12
- 206010008342 Cervix carcinoma Diseases 0.000 description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 10
- 201000010881 cervical cancer Diseases 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000012128 staining reagent Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- -1 haptens Proteins 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- 102400001301 Gasdermin-B, C-terminal Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000009595 pap smear Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000004043 dyeing Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 101150070189 CIN3 gene Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 4
- 101150061050 CIN1 gene Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 2
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000254158 Lampyridae Species 0.000 description 2
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- NMOJAXCSURVGEY-UHFFFAOYSA-N N#CC#N.[S] Chemical compound N#CC#N.[S] NMOJAXCSURVGEY-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 208000016420 cervical intraepithelial neoplasia grade 2/3 Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 2
- 229940011411 erythrosine Drugs 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
- 238000001506 fluorescence spectroscopy Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000005375 photometry Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229940043267 rhodamine b Drugs 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- FQBAHQUMQDHTQG-UHFFFAOYSA-N 1-chloro-2-methoxyacridine Chemical class C1=CC=CC2=CC3=C(Cl)C(OC)=CC=C3N=C21 FQBAHQUMQDHTQG-UHFFFAOYSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical class C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- JABNPSKWVNCGMX-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 JABNPSKWVNCGMX-UHFFFAOYSA-N 0.000 description 1
- NSMMFSKPGXCMOE-UHFFFAOYSA-N 2-[2-(2-sulfophenyl)ethenyl]benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1C=CC1=CC=CC=C1S(O)(=O)=O NSMMFSKPGXCMOE-UHFFFAOYSA-N 0.000 description 1
- CPBJMKMKNCRKQB-UHFFFAOYSA-N 3,3-bis(4-hydroxy-3-methylphenyl)-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=CC(C2(C3=CC=CC=C3C(=O)O2)C=2C=C(C)C(O)=CC=2)=C1 CPBJMKMKNCRKQB-UHFFFAOYSA-N 0.000 description 1
- SMBSZJBWYCGCJP-UHFFFAOYSA-N 3-(diethylamino)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(N(CC)CC)=CC2=C1 SMBSZJBWYCGCJP-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- OSWZKAVBSQAVFI-UHFFFAOYSA-N 4-[(4-isothiocyanatophenyl)diazenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(N=C=S)C=C1 OSWZKAVBSQAVFI-UHFFFAOYSA-N 0.000 description 1
- MZWWAGMOVQUICZ-UHFFFAOYSA-N 4-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenol hydrate trihydrochloride Chemical compound O.Cl.Cl.Cl.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C=C4N=C(NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 MZWWAGMOVQUICZ-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
- SJQRQOKXQKVJGJ-UHFFFAOYSA-N 5-(2-aminoethylamino)naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1S(O)(=O)=O SJQRQOKXQKVJGJ-UHFFFAOYSA-N 0.000 description 1
- ZWONWYNZSWOYQC-UHFFFAOYSA-N 5-benzamido-3-[[5-[[4-chloro-6-(4-sulfoanilino)-1,3,5-triazin-2-yl]amino]-2-sulfophenyl]diazenyl]-4-hydroxynaphthalene-2,7-disulfonic acid Chemical compound OC1=C(N=NC2=CC(NC3=NC(NC4=CC=C(C=C4)S(O)(=O)=O)=NC(Cl)=N3)=CC=C2S(O)(=O)=O)C(=CC2=C1C(NC(=O)C1=CC=CC=C1)=CC(=C2)S(O)(=O)=O)S(O)(=O)=O ZWONWYNZSWOYQC-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- SGAOZXGJGQEBHA-UHFFFAOYSA-N 82344-98-7 Chemical compound C1CCN2CCCC(C=C3C4(OC(C5=CC(=CC=C54)N=C=S)=O)C4=C5)=C2C1=C3OC4=C1CCCN2CCCC5=C12 SGAOZXGJGQEBHA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 241000522215 Dipteryx odorata Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100412856 Mus musculus Rhod gene Proteins 0.000 description 1
- IXQIUDNVFVTQLJ-UHFFFAOYSA-N Naphthofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C(C=CC=1C3=CC=C(O)C=1)=C3OC1=C2C=CC2=CC(O)=CC=C21 IXQIUDNVFVTQLJ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229910052771 Terbium Inorganic materials 0.000 description 1
- 101100242191 Tetraodon nigroviridis rho gene Proteins 0.000 description 1
- QHNORJFCVHUPNH-UHFFFAOYSA-L To-Pro-3 Chemical compound [I-].[I-].S1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 QHNORJFCVHUPNH-UHFFFAOYSA-L 0.000 description 1
- ZVUUXEGAYWQURQ-UHFFFAOYSA-L Yo-Pro-3 Chemical compound [I-].[I-].O1C2=CC=CC=C2[N+](C)=C1C=CC=C1C2=CC=CC=C2N(CCC[N+](C)(C)C)C=C1 ZVUUXEGAYWQURQ-UHFFFAOYSA-L 0.000 description 1
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 1
- JSBNEYNPYQFYNM-UHFFFAOYSA-J YoYo-3 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=CC=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC(=[N+](C)C)CCCC(=[N+](C)C)CC[N+](C1=CC=CC=C11)=CC=C1C=CC=C1N(C)C2=CC=CC=C2O1 JSBNEYNPYQFYNM-UHFFFAOYSA-J 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- IVHDZUFNZLETBM-IWSIBTJSSA-N acridine red 3B Chemical compound [Cl-].C1=C\C(=[NH+]/C)C=C2OC3=CC(NC)=CC=C3C=C21 IVHDZUFNZLETBM-IWSIBTJSSA-N 0.000 description 1
- BGLGAKMTYHWWKW-UHFFFAOYSA-N acridine yellow Chemical compound [H+].[Cl-].CC1=C(N)C=C2N=C(C=C(C(C)=C3)N)C3=CC2=C1 BGLGAKMTYHWWKW-UHFFFAOYSA-N 0.000 description 1
- AKOTUSVTEFJFAX-UHFFFAOYSA-N acridine;isothiocyanic acid Chemical class N=C=S.C1=CC=CC2=CC3=CC=CC=C3N=C21 AKOTUSVTEFJFAX-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000001000 anthraquinone dye Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- AFYCEAFSNDLKSX-UHFFFAOYSA-N coumarin 460 Chemical compound CC1=CC(=O)OC2=CC(N(CC)CC)=CC=C21 AFYCEAFSNDLKSX-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- AJMSJNPWXJCWOK-UHFFFAOYSA-N pyren-1-yl butanoate Chemical compound C1=C2C(OC(=O)CCC)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 AJMSJNPWXJCWOK-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- COIVODZMVVUETJ-UHFFFAOYSA-N sulforhodamine 101 Chemical compound OS(=O)(=O)C1=CC(S([O-])(=O)=O)=CC=C1C1=C(C=C2C3=C4CCCN3CCC2)C4=[O+]C2=C1C=C1CCCN3CCCC2=C13 COIVODZMVVUETJ-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
- G16Z99/00—Subject matter not provided for in other main groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Engineering & Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711037694.6A CN107699618B (zh) | 2010-11-12 | 2011-11-10 | 非疾病诊断的确定宫颈上皮内瘤样(cin)细胞是否存在于来自受试者的标记液体宫颈细胞样本的方法和系统 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41330210P | 2010-11-12 | 2010-11-12 | |
US61/413,302 | 2010-11-12 | ||
US201161484142P | 2011-05-09 | 2011-05-09 | |
US61/484,142 | 2011-05-09 | ||
PCT/US2011/060270 WO2012065004A2 (en) | 2010-11-12 | 2011-11-10 | Methods and systems for predicting whether a subject has a cervical intraepithelial neoplasia (cin) lesion from a suspension sample of cervical cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711037694.6A Division CN107699618B (zh) | 2010-11-12 | 2011-11-10 | 非疾病诊断的确定宫颈上皮内瘤样(cin)细胞是否存在于来自受试者的标记液体宫颈细胞样本的方法和系统 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103270419A CN103270419A (zh) | 2013-08-28 |
CN103270419B true CN103270419B (zh) | 2017-12-05 |
Family
ID=46048105
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180061996.1A Expired - Fee Related CN103270419B (zh) | 2010-11-12 | 2011-11-10 | 用于通过宫颈细胞的悬液样本预测受试者是否具有宫颈上皮内瘤样(cin)病变的方法和系统 |
CN201711037694.6A Expired - Fee Related CN107699618B (zh) | 2010-11-12 | 2011-11-10 | 非疾病诊断的确定宫颈上皮内瘤样(cin)细胞是否存在于来自受试者的标记液体宫颈细胞样本的方法和系统 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711037694.6A Expired - Fee Related CN107699618B (zh) | 2010-11-12 | 2011-11-10 | 非疾病诊断的确定宫颈上皮内瘤样(cin)细胞是否存在于来自受试者的标记液体宫颈细胞样本的方法和系统 |
Country Status (6)
Country | Link |
---|---|
US (3) | US10011884B2 (zh) |
EP (2) | EP2638396B1 (zh) |
JP (3) | JP6109744B2 (zh) |
CN (2) | CN103270419B (zh) |
ES (1) | ES2627069T3 (zh) |
WO (1) | WO2012065004A2 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12018857B2 (en) | 2008-06-13 | 2024-06-25 | Kateeva, Inc. | Gas enclosure assembly and system |
US10434804B2 (en) | 2008-06-13 | 2019-10-08 | Kateeva, Inc. | Low particle gas enclosure systems and methods |
US11975546B2 (en) | 2008-06-13 | 2024-05-07 | Kateeva, Inc. | Gas enclosure assembly and system |
US12064979B2 (en) | 2008-06-13 | 2024-08-20 | Kateeva, Inc. | Low-particle gas enclosure systems and methods |
JP2016503898A (ja) | 2013-01-14 | 2016-02-08 | インセルディーエックス・インコーポレーテッド | 子宮頸部細胞試料が子宮頸癌検査されるべきか判定する方法並びに該方法を実施する装置及びキット |
CN105210083B (zh) * | 2013-03-15 | 2019-05-21 | 霍罗杰克股份有限公司 | 用于查验和分析细胞学标本的系统和方法 |
US10468279B2 (en) | 2013-12-26 | 2019-11-05 | Kateeva, Inc. | Apparatus and techniques for thermal treatment of electronic devices |
KR102022816B1 (ko) | 2014-01-21 | 2019-11-04 | 카티바, 인크. | 전자 장치 인캡슐레이션을 위한 기기 및 기술 |
CN106233449B (zh) | 2014-04-30 | 2019-07-12 | 科迪华公司 | 用于衬底涂覆的气垫设备和技术 |
WO2016014861A1 (en) | 2014-07-25 | 2016-01-28 | Incelldx, Inc. | Methods of evaluating a cellular sample for latent cellular replication competent hiv-1, and compositions and kits for use in practicing the same |
CN114410830A (zh) * | 2014-09-17 | 2022-04-29 | 豪洛捷公司 | 部分裂解和测定的方法 |
ES2870474T3 (es) * | 2015-05-26 | 2021-10-27 | Incelldx Inc | Métodos de evaluación de muestras celulares de mama y composiciones para uso en practicar los mismos |
EP3719143B1 (en) * | 2015-10-23 | 2023-07-26 | Novartis AG | Method of deriving a value for percent biomarker positivity for selected cells present in a field of view |
JP7260960B2 (ja) * | 2018-03-29 | 2023-04-19 | シスメックス株式会社 | 検体前処理装置、ロボットアームおよび検体前処理方法 |
JP2021531790A (ja) * | 2018-07-27 | 2021-11-25 | ベンタナ メディカル システムズ, インコーポレイテッド | 自動化された原位置ハイブリッド形成分析のためのシステム |
US10769784B2 (en) * | 2018-12-21 | 2020-09-08 | Metal Industries Research & Development Centre | Image analyzing method and electrical device |
CN110335686B (zh) * | 2019-06-06 | 2023-07-04 | 广州金域医学检验中心有限公司 | 细胞类型识别方法、装置、计算机设备及存储介质 |
CN112529843A (zh) * | 2020-11-23 | 2021-03-19 | 集美大学 | 一种用于识别异常上皮细胞的方法和系统 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006052822A2 (en) * | 2004-11-05 | 2006-05-18 | Cytolution, Inc. | Methods and devices for screening cervical cancer |
WO2006084155A1 (en) * | 2005-02-02 | 2006-08-10 | Patterson Bruce K | Hpv e6, e7 mrna assay and methods of use thereof |
CN101831490A (zh) * | 2009-03-12 | 2010-09-15 | 上海市第八人民医院 | 一种利用pax1和cdh1基因甲基化检测宫颈癌的方法和试剂盒 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2955591A (en) | 1954-05-20 | 1960-10-11 | Kenneth S Maclean | Abrasive cytologic instruments |
US3626470A (en) | 1969-08-28 | 1971-12-07 | Armour Pharma | Diagnostic device for obtaining cytologic samples |
GB1408140A (en) | 1971-12-09 | 1975-10-01 | Levene M M | Sampling device |
US3877464A (en) | 1972-06-07 | 1975-04-15 | Andrew R Vermes | Intra-uterine biopsy apparatus |
US3815580A (en) | 1972-08-31 | 1974-06-11 | C Oster | Apparatus for and method of collecting and preserving cytologic samples |
US3945372A (en) | 1973-06-01 | 1976-03-23 | Milan Albert R | Medical tissue-obtaining system |
US4127113A (en) | 1977-12-15 | 1978-11-28 | Pap Smear Center, Inc. | Multiple smear brush |
US4175008A (en) | 1978-06-26 | 1979-11-20 | Bio-Pharmaceutical Packaging Corp. | Culture specimen collection and transport package |
JPS59109840A (ja) | 1982-12-16 | 1984-06-25 | Hitachi Koki Co Ltd | 走査形電子顕微鏡用生物試料の前処理方法 |
US4862899A (en) | 1985-05-02 | 1989-09-05 | Bucaro Russell J | Kit for home use detection of cervical and vaginal cancer |
NL8503596A (nl) | 1985-12-31 | 1987-07-16 | Futura Nova Bv | Inrichting voor het maken van een uitstrijk van een lichaamsholte. |
US4745285A (en) | 1986-08-21 | 1988-05-17 | Becton Dickinson And Company | Multi-color fluorescence analysis with single wavelength excitation |
US4867908A (en) | 1986-08-29 | 1989-09-19 | Becton, Dickinson And Company | Method and materials for calibrating flow cytometers and other analysis instruments |
US4704891A (en) | 1986-08-29 | 1987-11-10 | Becton, Dickinson And Company | Method and materials for calibrating flow cytometers and other analysis instruments |
US4762133A (en) | 1987-03-20 | 1988-08-09 | Medical Dynamics, Inc. | Cervical cytology device |
US4873992A (en) | 1987-03-20 | 1989-10-17 | Medical Dynamics, Inc. | Cervical cytology device |
US4754764A (en) | 1987-03-20 | 1988-07-05 | Medical Dynamics, Inc. | Cervical cytology device |
US4953560A (en) | 1989-12-07 | 1990-09-04 | Bernard Samuels | Apparatus, method, and test kit for diagnosis of vaginal yeast infections |
IE76732B1 (en) | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
CA2087086A1 (en) | 1992-01-22 | 1993-07-23 | Leon Wmm Terstappen | Multidimensional cell differential analysis |
US5422277A (en) * | 1992-03-27 | 1995-06-06 | Ortho Diagnostic Systems Inc. | Cell fixative composition and method of staining cells without destroying the cell surface |
US5342790A (en) | 1992-10-30 | 1994-08-30 | Becton Dickinson And Company | Apparatus for indirect fluorescent assay of blood samples |
US5445164A (en) | 1993-05-11 | 1995-08-29 | Gynetech, Inc. | Cervical tissue sampling device |
US5787891A (en) | 1995-03-16 | 1998-08-04 | Sak; Robert | Method and apparatus for sampling cervical tissue |
US5620842A (en) | 1995-03-29 | 1997-04-15 | Becton Dickinson And Company | Determination of the number of fluorescent molecules on calibration beads for flow cytometry |
US5701012A (en) | 1996-03-19 | 1997-12-23 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Fluorescent biological particle detection system |
US5895922A (en) | 1996-03-19 | 1999-04-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Fluorescent biological particle detection system |
US5858683A (en) * | 1996-08-30 | 1999-01-12 | Matritech, Inc. | Methods and compositions for the detection of cervical cancer |
US5795309A (en) | 1997-07-10 | 1998-08-18 | Leet; Richard A. | Cervical tissue sampling and containment device |
US6256096B1 (en) | 1999-01-11 | 2001-07-03 | Softray | Flow cytometry apparatus and method |
US6608682B2 (en) | 1999-01-25 | 2003-08-19 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells |
US6707551B2 (en) | 2000-01-24 | 2004-03-16 | Amnis Corporation | Multipass cavity for illumination and excitation of moving objects |
US6975400B2 (en) | 1999-01-25 | 2005-12-13 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells |
US7057732B2 (en) | 1999-01-25 | 2006-06-06 | Amnis Corporation | Imaging platform for nanoparticle detection applied to SPR biomolecular interaction analysis |
US6580504B1 (en) | 1999-01-25 | 2003-06-17 | Amnis Corporation | Multipass cavity for illumination and excitation of moving objects |
US6249341B1 (en) | 1999-01-25 | 2001-06-19 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells |
US6671044B2 (en) | 1999-01-25 | 2003-12-30 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells in broad flat flow |
US6473176B2 (en) | 1999-01-25 | 2002-10-29 | Amnis Corporation | Imaging and analyzing parameters of small moving objects such as cells |
US7450229B2 (en) | 1999-01-25 | 2008-11-11 | Amnis Corporation | Methods for analyzing inter-cellular phenomena |
BR0112385A (pt) | 2000-06-21 | 2003-06-17 | Digene Corp | Meio de coleta universal |
US6583865B2 (en) | 2000-08-25 | 2003-06-24 | Amnis Corporation | Alternative detector configuration and mode of operation of a time delay integration particle analyzer |
EP1328894A4 (en) | 2000-08-25 | 2005-11-09 | Amnis Corp | MEASURING THE SPEED OF SMALL MOBILE OBJECTS SUCH AS CELLS |
US6934408B2 (en) | 2000-08-25 | 2005-08-23 | Amnis Corporation | Method and apparatus for reading reporter labeled beads |
US6875973B2 (en) | 2000-08-25 | 2005-04-05 | Amnis Corporation | Auto focus for a flow imaging system |
US6778263B2 (en) | 2000-08-25 | 2004-08-17 | Amnis Corporation | Methods of calibrating an imaging system using calibration beads |
US6608680B2 (en) | 2000-08-25 | 2003-08-19 | Amnis Corporation | TDI imaging system for kinetic studies |
US6563583B2 (en) | 2000-10-12 | 2003-05-13 | Amnis Corporation | Multipass cavity for illumination and excitation of moving objects |
AU2002213157A1 (en) | 2000-10-12 | 2002-04-22 | Amnis Corporation | System and method for high numeric aperture imaging systems |
US6387058B1 (en) | 2000-10-13 | 2002-05-14 | Wallach Surgical Devices, Inc. | Self-sampling brush and method for use |
ES2380261T3 (es) * | 2000-11-17 | 2012-05-10 | Biomoda, Inc. | Composiciones y métodos para la detección de afecciones precancerosas en muestras de células y tejidos utilizando 5, 10, 15, 20-tetrakis(carboxifenil)porfina. |
US6329167B1 (en) | 2000-12-05 | 2001-12-11 | Bruce K. Patterson | Method of testing adequacy of cells in a specimen |
EP1389956B1 (en) | 2001-04-25 | 2012-10-31 | Amnis Corporation | Method and apparatus for correcting crosstalk and spatial resolution for multichannel imaging |
US6618140B2 (en) | 2001-06-18 | 2003-09-09 | Amnis Corporation | Spectral deconvolution of fluorescent markers |
US20030017516A1 (en) * | 2001-06-26 | 2003-01-23 | Trustees Of Tufts College | Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer |
WO2003009579A2 (en) | 2001-07-17 | 2003-01-30 | Amnis Corporation | Computational methods for the segmentation of images of objects from background in a flow imaging instrument |
EP1422526A1 (en) * | 2002-10-28 | 2004-05-26 | MTM Laboratories AG | Method for improved diagnosis of dysplasias |
US7610942B2 (en) | 2003-01-15 | 2009-11-03 | Amnis Corporation | Cell suspension rotating fluidic pump |
US20040260157A1 (en) | 2003-06-20 | 2004-12-23 | Montes Miguel A. | Method for automated screening of cervical/endocervical malignant and premalignant epithelial lesions using flow cytometry with HPV DNA fluorescent in-situ hybridization ( FISH) technology |
AU2005228026B2 (en) * | 2004-03-24 | 2011-03-24 | Tripath Imaging, Inc. | Methods and compositions for the detection of cervical disease |
US20050221399A1 (en) | 2004-03-30 | 2005-10-06 | Sysmex Corporation | Method for screening cervical cancer |
JP2005315862A (ja) * | 2004-03-30 | 2005-11-10 | Sysmex Corp | 子宮頸癌のスクリーニング方法及び子宮頸癌診断薬 |
KR100633525B1 (ko) * | 2004-10-04 | 2006-10-16 | 굿젠 주식회사 | 인체유두종바이러스의 프로브, 이를 포함하는올리고뉴클레오티드 마이크로어레이, 진단키트 및 이를이용한 유전자형 분석방법 |
DE102004052816A1 (de) | 2004-10-29 | 2006-05-04 | Mefro Räderwerk Ronneburg GmbH | Spurverstellrad und Verfahren zur Herstellung eines Spurverstellrads |
US8865162B2 (en) * | 2008-06-13 | 2014-10-21 | Oncohealth Corp. | Monoclonal antibodies against HPV proteins |
CN104122191B (zh) * | 2007-10-29 | 2020-02-18 | 希森美康株式会社 | 细胞分析仪及细胞分析方法 |
US20100234445A1 (en) | 2008-07-01 | 2010-09-16 | Weng Onn Lui | Patterns of known and novel small RNAS in human cervical cancer |
KR20110049830A (ko) * | 2008-07-30 | 2011-05-12 | 시스멕스 가부시키가이샤 | 자궁 경부 이상세포 검출용 시약 및 그것을 이용하는 자궁 경부 이상세포 검출 방법 |
US7897356B2 (en) | 2008-11-12 | 2011-03-01 | Caris Life Sciences | Methods and systems of using exosomes for determining phenotypes |
US8865882B2 (en) | 2010-09-08 | 2014-10-21 | Cancer Genetics, Inc. | Methods for detecting human papilloma virus-associated cancers |
-
2011
- 2011-11-10 EP EP11839907.0A patent/EP2638396B1/en active Active
- 2011-11-10 CN CN201180061996.1A patent/CN103270419B/zh not_active Expired - Fee Related
- 2011-11-10 WO PCT/US2011/060270 patent/WO2012065004A2/en active Application Filing
- 2011-11-10 EP EP17157150.8A patent/EP3217178A3/en not_active Ceased
- 2011-11-10 ES ES11839907.0T patent/ES2627069T3/es active Active
- 2011-11-10 CN CN201711037694.6A patent/CN107699618B/zh not_active Expired - Fee Related
- 2011-11-10 JP JP2013538911A patent/JP6109744B2/ja active Active
- 2011-11-10 US US13/294,101 patent/US10011884B2/en active Active
-
2015
- 2015-05-19 US US14/716,493 patent/US10167526B2/en active Active
-
2016
- 2016-12-08 JP JP2016238454A patent/JP6505657B2/ja active Active
-
2017
- 2017-01-25 US US15/415,476 patent/US20170130281A1/en active Pending
-
2019
- 2019-03-27 JP JP2019060424A patent/JP2019124701A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006052822A2 (en) * | 2004-11-05 | 2006-05-18 | Cytolution, Inc. | Methods and devices for screening cervical cancer |
WO2006084155A1 (en) * | 2005-02-02 | 2006-08-10 | Patterson Bruce K | Hpv e6, e7 mrna assay and methods of use thereof |
CN101831490A (zh) * | 2009-03-12 | 2010-09-15 | 上海市第八人民医院 | 一种利用pax1和cdh1基因甲基化检测宫颈癌的方法和试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
US20120122078A1 (en) | 2012-05-17 |
WO2012065004A2 (en) | 2012-05-18 |
EP2638396A2 (en) | 2013-09-18 |
JP2017058379A (ja) | 2017-03-23 |
CN107699618A (zh) | 2018-02-16 |
EP2638396A4 (en) | 2014-04-30 |
ES2627069T3 (es) | 2017-07-26 |
US20170130281A1 (en) | 2017-05-11 |
CN107699618B (zh) | 2021-08-20 |
CN103270419A (zh) | 2013-08-28 |
WO2012065004A3 (en) | 2012-07-05 |
JP6109744B2 (ja) | 2017-04-05 |
US10011884B2 (en) | 2018-07-03 |
EP3217178A2 (en) | 2017-09-13 |
US20150259756A1 (en) | 2015-09-17 |
JP2013542452A (ja) | 2013-11-21 |
JP6505657B2 (ja) | 2019-04-24 |
EP3217178A3 (en) | 2017-11-22 |
JP2019124701A (ja) | 2019-07-25 |
US10167526B2 (en) | 2019-01-01 |
EP2638396B1 (en) | 2017-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103270419B (zh) | 用于通过宫颈细胞的悬液样本预测受试者是否具有宫颈上皮内瘤样(cin)病变的方法和系统 | |
CN102066931B (zh) | 人乳头状瘤病毒早期及晚期感染之免疫分析试验 | |
JP2021506013A (ja) | 腫瘍空間異質性およびインターマーカ異質性の計算方法 | |
US7452727B2 (en) | Method for increasing clinical specificity when detecting tumors and their precursor stages by simultaneously measuring at least two different molecular markers | |
US10060905B2 (en) | Liquid medium and sample vial for use in a method for detecting cancerous cells in a cell sample | |
US20130338016A1 (en) | Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis | |
JP2004526154A5 (zh) | ||
CN104094116A (zh) | 在哺乳动物个体中检测5t4阳性循环肿瘤细胞的方法和诊断5t4阳性癌症的方法 | |
JP2008116466A (ja) | 子宮頸部塗抹標本における腫瘍細胞およびそれらの前駆体の検出方法 | |
CN106932579B (zh) | 一种基于液体活检的肝癌检测的试剂盒 | |
Wu et al. | The diagnostic utility of p16 immunostaining in differentiating cancer and HSIL from LSIL and benign in cervical cells | |
Connolly et al. | Role of the Surgical Pathologist in the Diagnosis and Management of the Cancer Patient | |
CN106841620B (zh) | 一种基于液体活检的结直肠癌检测的试剂盒 | |
CN106290874B (zh) | 对肝细胞癌患者进行肝移植术预后情况分组的方法、系统以及试剂盒 | |
CN107850526B (zh) | 评估细胞乳腺样品的方法和用于实践所述方法的组合物 | |
AU2012252532A1 (en) | Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ analysis | |
Dickinson | Canine lymphosarcoma: Overcoming diagnostic obstacles and introduction to the latest diagnostic techniques | |
CN106990080B (zh) | 一种基于液体活检的非小细胞肺癌检测的试剂盒 | |
CN106970221B (zh) | 一种基于液体活检的前列腺癌检测的试剂盒 | |
Hemstreet III et al. | Quantitative fluorescence image analysis in bladder cancer screening | |
Lau et al. | Advances in imaging modalities, artificial intelligence, and single cell biomarker analysis, and their applications in cytopathology | |
CN102576024B (zh) | 宫颈癌细胞和/或组织的鉴别染色的试剂盒和方法 | |
CN105122064A (zh) | 确定针对子宫颈癌是否应该测试子宫颈细胞样本的方法及用于实施其的装置和试剂盒 | |
Wojcik | Urine cytology, DNA ploidy and morphometry | |
EP4217746A1 (en) | Diagnosis of cancer by imaging flow cytometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1188628 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1188628 Country of ref document: HK |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20130828 Assignee: GUANGZHOU IMPROVE MEDICAL TECHNOLOGY Co.,Ltd. Assignor: INCELLDX, INC. Contract record no.: X2019990000041 Denomination of invention: METHODS AND SYSTEMS FOR PREDICTING WHETHER A SUBJECT HAS A CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) LESION FROM A SUSPENSION SAMPLE OF CERVICAL CELLS Granted publication date: 20171205 License type: Exclusive License Record date: 20190823 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171205 |
|
CF01 | Termination of patent right due to non-payment of annual fee |